PRRT2 and breast cancer: The only exception to the activation of classical PKCs came appeared to be PKCβII as an anti- PKC pan-βII (Ser660) antibody failed to detect differences between the groups (Figure 3f-3h) and hence chemoresistance of breast cancer cells involves prominent activation of classical PKCs.